Extramedullary Plasmacytoma
Conditions
Keywords
Bortezomib
Brief summary
The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.
Interventions
DRUGCDD
Chemotherapy
DRUGCDD Plus Bortezomib
Chemotherapy plus Proteasome Inhibitors
Sponsors
Peking University People's Hospital
Beijing Chao Yang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients from 18 to 80 * Biopsy-proven EMP with relapsed or refractory Myeloma disease. Patients may be proteasome inhibitor-exposed or naive, but cannot be refractory to proteasome inhibitor therapy * Disease requiring further treatment * Measurable disease such as M protein and Objective and measurable of EMP * Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 * Meet the clinical laboratories criteria as specified in the protocol * Voluntary written consent
Exclusion criteria
* Female patients who are lactating, breastfeeding or pregnant * Evidence of current uncontrolled cardiovascular conditions as specified in study protocol * Requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, which would be considered as a treatment of EMP. * Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Ongoing or active infection, known HIV positive, active hepatitis B or C infection * Psychiatric illness/social situations that would limit compliance with study requirements * Known allergy to any of the study medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with overall hematologic response | Assessed every 2 cycles (median length of the endpoint assessment period is projected to be approximately 24 months) | Complete response, very good partial response and partial response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Monthly up to 3 years | The median overall survival |
| Time from diagnosis ofEMP to the date of death | Monthly up to 3 years | — |
| Number of patients with EMP response | Assessed every 2 cyeles period is projected to be approximately 24 months | response rate |
| Time from date of diagnosis of EMP to the date of first documentation of disease | Monthly up to 2 years | — |
| Number of adverse events | Monthly up to 3 years | Adverse events, serious adverse events, assessment of clinical laboratory values from the date of signing of the informed consent form through 30 days after the last dose of study drug. |
| Progression free survival | Monthly up to 2 years | — |
Countries
China
Contacts
Primary ContactYuping ZHONG, Doctor
Outcome results
None listed